UK-based speciality chemicals company Croda built a current good manufacturing practice (cGMP) lipid systems manufacturing facility in Lamar, Pennsylvania, US.
The facility expands the company’s manufacturing capacity for the development of lipids used in delivery systems for new complex therapeutic drugs.
Recommended Buyers Guides
The new facility is Croda’s third manufacturing site for lipid systems, following its two existing sites, Avanti Polar Lipids in Alabaster, Alabama, and a manufacturing facility in Leek, UK.
The Lamar facility supports the company in expanding its portfolio of patient healthcare solutions.
Croda built the facility in cooperation with the US Government, which provided up to $75m. The company invested up to $58m (£43.27m) in the project, bringing the total estimated project investment to up to $133m.
Construction on the Lamar facility began in June 2023 and the facility was opened in March 2025.
The project created around 50 new jobs spanning engineering, administration, maintenance, operations and logistics.
Location of Croda’s facility in Lamar, Pennsylvania
The lipid facility is part of a new 37-acre multi-purpose cGMP site at 88 Heckman’s Gap Road in the Lamar Township Business Park. Croda purchased the site in June 2021.
Details of Croda’s lipid systems facility
The 23,680ft2 (2,199m2) lipid systems facility was developed as part of a strategic collaboration with the US Government’s Administration for Strategic Preparedness and Response’s Biomedical Advanced Research and Development Authority programme to expand its industrial base to support critical vaccine and therapeutic manufacturing activities.
The increased capacity enhances the manufacturing of essential ingredients for vaccine production, thereby strengthening the government’s preparedness for future health emergencies.
Lipid systems have enormous potential as a means of delivering nucleic acid applications, including advanced messenger RNA (mRNA)-based therapeutics such as cancer treatments and influenza vaccines.
Multi-purpose cGMP site development details
Croda’s development project plan for the multi-purpose cGMP site in Lamar Township was approved by the Clinton County Planning Commission in August 2021.
The property was a former BJ Services industrial site with seven pre-existing buildings including a flammable warehouse, a fuel dispensing station, a vehicle maintenance building, and an office or laboratory, four of which were repurposed.
Croda converted the vehicle maintenance area into a production area to manufacture speciality chemicals.
Lipids in mRNA vaccine delivery and therapeutic use
Lipids, the building blocks of cells, are organic, nonpolar molecules soluble in organic solvents but insoluble in water. They are used as solubilisers for active pharmaceutical ingredients, carriers for lipid-based delivery systems such as liposomes and agents for lipid-DNA transfection, for drug formulation and delivery.
Avanti Polar Lipids, a division of Croda, assists in the development of a broad range of cGMP-manufactured lipids and lipid derivatives, using lipid nanoparticle (LNP) technology to meet client demand for mRNA-based vaccines and therapeutics.
LNPs are lipid-based drug delivery systems that are used to carry nucleic acid material such as mRNA, while delivering it into the cell to protect it from degradation. The four main components used in these systems are polyethylene glycol lipid, an amino (cationic) lipid, a structural lipid and cholesterol.
The advanced drug delivery system has proven to be popular for developing vaccines for the coronavirus disease 2019 (Covid-19) due to its versatility.
Marketing commentary on Croda
Established in 1925, Croda provides sustainable, high-performance ingredients and technologies for consumer and healthcare markets.
The company’s acquisition of Avanti Polar Lipids in August 2020 allowed it to become the first to supply clinical and commercial quantities of crucial lipid systems required for global manufacturing of Covid-19 vaccines.
The company has an employee base of 6,100 across 37 locations worldwide. It generated £1.7bn in revenue in 2025.
